Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority trial of stopping valganciclovir prophylaxis in CMV-seropositive kidney transplant recipients
2015-004406-42Phase 3Completed
- Sponsor
- FIBICO
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by FIBICO. Primary endpoint: Incidence of CMV disease at 12 months after transplantation. Started Nov 2015; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2015-004406-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004406-42.